Marion McCourt; Executive Vice President - Commercial; Regeneron Pharmaceuticals Inc. Christopher Fenimore; Chief Financial Officer, Senior Vice President - Finance; Regeneron Pha ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Regeneron co-Chair, President and CSO George Yancopoulos discusses the company's planned weight-loss drugs with Katie Greifeld at the JPMorgan Healthcare Conference in San Francisco. Slimming ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

“Big Data—combined with human ingenuity—is the key to driving next-generation scientific advancements,” added George Yancopoulos, M.D., Ph.D., president and chief scientific officer of ...

Regeneron and Teva have announced positive top-line phase 3 results from their fasinumab, as the companies chase Pfizer and Lilly in the race to market a new class of non-opioid painkillers.

which are ideal for extracellular targets and those on the cell surface,” said George Yancopoulos, president and chief scientific officer of Regeneron. “Through the RGC and our other research ...

When the GPR75 researh was published, Regeneron's chief scientific officer George Yancopoulos, described the mutations as a "genetic superpower" that "provides hope in combating global health ...

The conference, entitled “Healthcare Beyond Borders,” included talks from two keynote speakers, panel sessions, and a career ...

in earlier lines of therapy," said Regeneron's chief scientific officer George Yancopoulos. "We're also excited to be advancing our broader pipeline of CD3 and other bispecific therapies ...

as well as enable new approaches to healthcare analytics and healthcare management," remarked Regeneron's chief scientific officer, George Yancopoulos.